R&D | December 05, 2025
DBT, BIRAC and CEPI renew cooperation agreement for vaccine development
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
The move is expected to be crucial during health crises
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
Subscribe To Our Newsletter & Stay Updated
